Gennova�s m RNA vaccine gets clearance for Phase 2/3 clinical trials

[email protected]12 Oct, 2021News

India?s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday. The development of HGCO19, the country?s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India?s target of vaccinating all adults by the end of the year as senior government officials have said that ? subject to trials and approval ? they are looking at availability of 60 million vaccine doses by December.